Key events
The meeting called for continuous efforts to ensure the quality and supply of covid-19 virus vaccine, accelerate the approval and listing of covid-19 virus therapeutic drugs and covid-19 virus antigen detection reagents, strengthen the quality supervision of epidemic prevention products, do a solid job in internal prevention and control, and fully serve the overall situation of epidemic prevention and control.
In March 15th, the National Health Council released the New Coronavirus pneumonia diagnosis and treatment plan (trial version ninth). The new version of the treatment plan revised the transmission characteristics and pathological characteristics of the variant strains such as delta and Amy.
Comments
Covid-19 epidemic prevention and control requires multi pronged and integrated prevention and control. The meeting of the food and drug administration put forward requirements from three aspects: covid-19 vaccine, covid-19 therapeutic drugs and covid-19 antigen detection reagent, which is conducive to comprehensively promoting the improvement of covid-19 epidemic prevention and control means in China.
Compared with the eighth edition of the diagnosis and treatment plan released in April 2021, the key revisions of the ninth edition of covid-19 diagnosis and treatment plan include:
First, optimize the case discovery and reporting procedures. On the basis of nucleic acid detection, antigen detection is added as a supplement to further improve the ability of early detection of cases and improve the efficiency of diagnosis or exclusion of suspected cases.
The second is to classify the cases. According to the opinions of “patients with Omicron variant virus are mainly asymptomatic infected and light cases, most of them do not need too much treatment, and all of them will occupy a lot of medical resources when admitted to designated hospitals”, the case classification and treatment measures have been further improved: from the previous suspected and confirmed cases are treated in designated hospitals, they are modified to light cases, and centralized isolation management is implemented Ordinary / severe / dangerous cases and cases with severe high-risk factors should be treated in designated hospitals to reduce the burden of medical resources.
Third, further standardize antiviral treatment. Two specific anti-covid-19 drugs approved by the State Food and drug administration were written into the diagnosis and treatment plan, namely Pfizer covid-19 oral drug paxlovid (pf-07321332 / ritonavir tablets) and tengshengbo neutralizing antibody (ambavizumab / romistumab injection).
Fourth, the content of traditional Chinese medicine treatment has been revised and improved. Combined with local clinical treatment experience, the application of traditional Chinese medicine non drug therapy was strengthened, and the content of acupuncture and moxibustion treatment was added; Combined with the characteristics of children’s patients, add relevant contents of children’s traditional Chinese medicine treatment. The application of traditional Chinese medicine has also been further enriched and improved.
Fifth, adjust the release of isolation management and discharge standards, and shorten the release of isolation management and post discharge monitoring time.
We believe that, on the one hand, the adjustment of covid-19 diagnosis and treatment plan reflects China’s phased achievements in covid-19 detection, covid-19 specific drug R & D and approval, and the application of traditional Chinese medicine and other characteristic medical treatment. On the other hand, it also adapts to the changes of epidemic characteristics caused by mutant strains. At present, there are abundant R & D pipelines for covid-19 oral drugs and covid-19 vaccines in China. With the readout of clinical data of products under research and approval for listing, we will have a more perfect covid-19 prevention and treatment system.
Based on the accessibility and convenience of oral drug use, we hope that Pfizer’s Paxlovid dose in China ( China Meheco Group Co.Ltd(600056) is responsible for the commercial operation in Chinese mainland market). We hope that the follow-up Pfizer’s COVID-19 MPP will give the API/CDMO sector head business the performance elasticity.
Investment advice
Continue to be optimistic about the main line of epidemic prevention and the advanced manufacturing direction of medicine, including detection and killing, vaccines and specific drugs, their R & D industrial chain, upstream supply chain, etc.
It is suggested to focus on: Zhejiang Jiuzhou Pharmaceutical Co.Ltd(603456) , Zhejiang Hisun Pharmaceutical Co.Ltd(600267) , Apeloa Pharmaceutical Co.Ltd(000739) , China Meheco Group Co.Ltd(600056) , Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) , etc.
Risk tips
Covid-19 epidemic development and change risk, product R & D data and progress are less than expected risk, product capacity and sales are less than expected risk, orders are less than expected risk, competition is intensified risk, and policy supervision risk.
